Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02226250 · ClinicalTrials.gov registry record · NA
Absorption and Metabolic Profiles of a Sugar-based Beverage
A NA study of Healthy and Overweight, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT02226250: Completed NA study of Healthy and Overweight, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
NCT02226250 is a NA study of Healthy and Overweight that has completed, run by Clinical Nutrition Research Center, Illinois Institute of Technology. The registered enrollment target is 9 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02226250, a NA study of Healthy and Overweight, has completed, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary objective is to determine absorption profile of a sugar-based beverage on inflammatory mechanism by timing of beverage consumption relative to meal intake. Secondary objective is to determine absorption profile of a sugar-based beverage on oxidative and metabolic mechanism by timing of beverage consumption relative to meal intake. The results will be served as an internal reference or negative control group to compare with polyphenol containing studies from other studies. Each subject will receive 3 identical placebo drinks at each time points: fasting (0h), with standardized breakfast meal (2h), and 2 hours after the breakfast meal (4h). A planned size of 12 will be recruited into this part of the study. This study is a single-arm design utilizing a multiple sampling, and repeated measures paradigm to evaluate timing influence of consumption of sugar-based beverage associated acute effect on inflammatory markers.
Primary Outcome
The timing influence of beverage consumption on inflammation markers in relative to meal intake (2 hours before a meal, with a meal, and 2 hours after a meal).
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT 3 Placebo Beverages
Study Locations (1)
Illinois
- Clinical Nutrition Research Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-06-26 |
| Est. Completion | 2015-02-20 |
| Phase | NA |
What the finished NCT02226250 record still lists
NCT02226250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which 3 Placebo Beverages is the first listed.
NCT02226250 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02226250 about?
NCT02226250 is a clinical study titled "Absorption and Metabolic Profiles of a Sugar-based Beverage". Primary objective is to determine absorption profile of a sugar-based beverage on inflammatory mechanism by timing of beverage consumption relative to meal intake. Secondary objective is to determine absorption profile of a sugar-based beverage on oxidative and metabolic mechanism by timing of beve...
What is the current status of trial NCT02226250?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2014-06-26. Estimated completion is 2015-02-20.
What conditions does trial NCT02226250 study?
This clinical trial studies the following conditions: Healthy, Overweight.
What interventions are being tested in trial NCT02226250?
The interventions under investigation include: 3 Placebo Beverages (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02226250?
This trial is sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02226250 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02226250's enrollment target sits among peer trials
9 1057th of 1090 higher than 31 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
-
Oxalate and Citrate in Humans - Response to Citrate
RECRUITING · NA
-
CArdioMEtabolic Function and Reserve Capacity in Healthy Adults: The CAMERA Study
RECRUITING · NA
-
Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia
RECRUITING · NA
-
Medical Illustration Design Characteristic Evaluation
RECRUITING · NA
-
Sodium vs Potassium Education to Improve Vascular Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI